VEGF165 is necessary to the metastatic potential of Fas - osteosarcoma cells but will not rescue the Fas+ cells

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 2, 2008, Pages 89-97

  Jia, Shu Fang ^a   Guan, Hui ^a   Duan, Xiaoping ^a   Kleinerman, Eugenie S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Cancer Biology ^*  (United States)

Author keywords

Fas; Lung metastases; Osteosarcoma; siVEGF165; VEGF165

Indexed keywords

FAS ANTIGEN; VASCULOTROPIN 165; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG METASTASIS; MOLECULAR CLONING; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BONE TUMOR; CELL MOTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE VECTOR; GENETICS; LUNG TUMOR; METASTASIS; MOUSE; NUDE MOUSE; OSTEOSARCOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD95; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49549116204     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Eiber F, Giuliano A, Eckardt J et al (1987) Adjuvant chemotherapy for osteo-sarcoma: a randomized prospective trial. J Clin Onc 5: 21-26.
2. Jaffe N (1986) Chemotherapy in osteosarcoma. In: Muggia FM (ed) Experimental and Clinical Progress in Cancer Chemotherapy, Martinus Nijhoff Publishers, Boston, Advances and Controversies, pp. 223-233.
3. Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606.
4. Goorin AM, Shuster JJ, Baker A et al (1991) Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from a multi-institutional osteosarcoma study. J Clin Oncol 9:600-605.
5. Fernando NH, Hurwitz HI (2003) Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Sem Oncol 30:39-50
6. Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Sem Oncol 29:10-14.
7. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543.
8. 189. Proc Natl Acad Science USA 94:12081-12087.
9. Oku T, Tjuvajev JG, Miyagawa Y et al (1998) Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, Fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 58:4185-4192.
10. Claffey KP, Brown LF, Del Angila LF et al (1996) Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56.172-181.
11. Ferrara N, Alitalo K ( 1999) Clinical applications of angiogenic growth factors and their inhibitors. Nature Med 5:1359-1364.
12. Ferrara N (2000) VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 11:617-624.
13. Guan H, Zhou Z, Wang H et al (2004) A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 11:2662-2669.
14. Jia S-F, Worth LL, Kleinerman ES (1999) A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Met 17:501-506.
15. Lafleur EA, Koshkina NV, Stewart J et al (2004) Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 10:8114-8119.
16. Jia S-F, Worth LL, Turan M et al (2002) Eradication of osteosarcoma lung metastasis using intranasal Gemcitabine. Anticancer Drugs 13:155-161.
17. Worth LL, Lafleur EA, Jia S-F et al (2002) Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9:823-827.
18. Okada F, Rak JW, Croix BS, et al (1998) Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Science USA 95:3609-3614.
19. Cheng SY, Huang HJ, Nagane M et al (1996) Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Science USA 93:8502-8507.
20. Owen-Schaub LB, van Golen KL, Hill LL et al (1998) Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 188:1717-1723.
21. Moller P, Koretz F, Leithauser F et al (1994) Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57:371-377.
22. Gordon N, Koshkina NV, Jia S-F et al (2007) Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential and reduces the effect of aerosol Gemcitabine. Clin Cancer Res 13:4503-4510.
23. Koshkina NV, Khanna C, Mendoza A et al (2007) Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role the Fas pathway in metastatic process of osteosarcoma. Molecular Cancer Res 10:991-999.
24. Khanna C, Khan J, Nguyen P et al (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61:3750-3759.
25. Jia S-F, Worth LL, Densmore CL et al (2003) Aerosol Gene Therapy with PEI:IL-12 Eradicates Osteosarcoma Lung Metastases. Clinical Cancer Res 9:3462-3468.
26. Duan X, Jia S-F, Koshkina N et al (2006) Intranasal Interleukin-12 Gene Therapy Enhanced the Activity of Ifosfamide Against Osteosarcoma Lung Metastases. Cancer 106:1382-1388.